Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project

No AccessJournal of UrologyAdult Urology1 Jan 2020Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America ProjectThis article is commented on by the following:Editorial CommentEditorial Comment Charles Welliver, Lydia Feinstein, Julia B. Ward, Chyng-Wen Fwu, Ziya Kirkali, Tamara Bavendam, Brian R. Matlaga, and Kevin T. McVary Charles WelliverCharles Welliver Division of Urology, Albany Medical College, Albany, New York More articles by this author , Lydia FeinsteinLydia Feinstein *Correspondence: Social & Scientific Systems, 4505 Emperor Blvd., Suite 400, Durham, North Carolina 27703 telephone: 919-287-4556; FAX: 919-941-9349; E-mail Address: [email protected] Social and Scientific Systems, Durham, North Carolina Financial interest and/or other relationship with Social & Scientific Systems. More articles by this author , Julia B. WardJulia B. Ward Social and Scientific Systems, Durham, North Carolina Financial interest and/or other relationship with Social & Scientific Systems. More articles by this author , Chyng-Wen FwuChyng-Wen Fwu Social and Scientific Systems, Durham, North Carolina Financial interest and/or other relationship with Social & Scientific Systems. More articles by this author , Ziya KirkaliZiya Kirkali National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland More articles by this author , Tamara BavendamTamara Bavendam National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland More articles by this author , Brian R. MatlagaBrian R. Matlaga Departments of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland Financial interest and/or other relationship with Boston Scientific and Social & Scientific Systems. More articles by this author , and Kevin T. McVaryKevin T. McVary Loyola University Medical Center, Maywood, Illinois More articles by this author for the Urologic Diseases in America Project View All Author Informationhttps://doi.org/10.1097/JU.0000000000000499AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Our current understanding of recent trends in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia is incomplete, particularly in younger men. The 2018 Urologic Diseases in America Project attempted to fill this gap by analyzing multiple large administrative claims databases which include men of all ages and permit longitudinal followup. To our knowledge we report these findings for the first time in the scientific literature. Materials and Methods: The 2 data sources used in this study included the de-identified Optum® Clinformatics® Data Mart database for men 40 to 64 years old and the Medicare 5% Sample for men 65 years old or older. To assess trends in lower urinary tract symptoms/benign prostatic hyperplasia related medication prescriptions and surgical procedures from 2004 to 2013 we created annual cross-sectional cohorts and a longitudinal cohort of patients with incident lower urinary tract symptoms/benign prostatic hyperplasia and 5 years of followup. Results: The use of medications related to lower urinary tract symptoms/benign prostatic hyperplasia increased with age, particularly among men 40 to 60 years old. While medication use increased with time, surgical procedures decreased. Increasing age correlated with a higher rate of surgical procedures in the longitudinal cohort. Younger men were more likely to elect treatments of lower urinary tract symptoms/benign prostatic hyperplasia which reportedly optimize sexual function. Conclusions: Medication use increased and surgery decreased during the study period. Treatment approaches to lower urinary tract symptoms/benign prostatic hyperplasia varied greatly by patient age. While the minority of men in the fifth and sixth decades of life required treatment, a sharp increase in treatment use was seen between these decades. Younger men were more likely to elect less invasive surgical options. Future studies of lower urinary tract symptoms/benign prostatic hyperplasia should focus on age specific treatment selection. References 1. : Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol 2018; 200: 612. Link, Google Scholar 2. : Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 1994; 44: 692. Google Scholar 3. : Transurethral resection of the prostate among Medicare beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases. J Urol 2000; 164: 1212. Link, Google Scholar 4. : Impact of medical therapy on transurethral resection of the prostate: two decades of change. BJU Int 2011; 108: 89. Google Scholar 5. : Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol 2008; 180: 241. Link, Google Scholar 6. : Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol 200; 405: 2018. Google Scholar 7. Urologic Diseases in America. Benign Prostatic Hyperplasia, NIH Publication No. 12-7865. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases. Google Scholar 8. : A review of pregnancy in women over 35 years of age. Open Nurs J 2009; 3: 33. Google Scholar 9. : The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85. Link, Google Scholar 10. : Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990; 17: 241. Google Scholar 11. : The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985; 121: 78. Google Scholar 12. : The incidence of benign prostatic obstruction. J Urol 1968; 99: 639. Link, Google Scholar 13. : National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology 2012; 79: 1111. Google Scholar 14. : An assessment of prostatectomy for benign urinary tract obstruction. Geographic variations and the evaluation of medical care outcomes. JAMA 1988; 259: 3027. Google Scholar 15. : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387. Google Scholar 16. : Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol 2014; 191: 1828. Link, Google Scholar 17. : Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality. BJU Int 2019; 123: 511. Google Scholar The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number. The UDA (Urologic Diseases in America) project was funded by the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) through a contract to Social & Scientific Systems (HHSN276201500204U). The data reported here have been supplied in part by the USRDS (United States Renal Data System). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the United States government. No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. Editor's Note: This article is the fourth of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 212 and 213. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byLeyh-Bannurah S, Liakos N, Oelke M, Wagner C, Schuette A, Fangmeyer B, Zinke J, Wasiri D, Mendrek M and Witt J (2021) Perioperative and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume CenterJournal of Urology, VOL. 206, NO. 2, (308-318), Online publication date: 1-Aug-2021.Frendl D, Chen Y, Chang D and Kim M (2020) A Claims Based Assessment of Reoperation and Acute Urinary Retention after Ambulatory Transurethral Surgery for Benign Prostatic HyperplasiaJournal of Urology, VOL. 205, NO. 2, (532-538), Online publication date: 1-Feb-2021.Seftel A (2020) Re: Association among Lower Urinary Tract Symptoms, Erectile Function, and Sexual Satisfaction: Results from the Brazil LUTS StudyJournal of Urology, VOL. 203, NO. 5, (863-864), Online publication date: 1-May-2020.Smith J (2019) This Month in Adult UrologyJournal of Urology, VOL. 203, NO. 1, (1-3), Online publication date: 1-Jan-2020.Related articlesJournal of Urology21 Oct 2019Editorial CommentJournal of Urology21 Oct 2019Editorial Comment Volume 203Issue 1January 2020Page: 171-178Supplementary Materials Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.Keywordsurologic surgical proceduresprostatic hyperplasiadrug prescriptionsage groupslower urinary tract symptomsMetricsAuthor Information Charles Welliver Division of Urology, Albany Medical College, Albany, New York More articles by this author Lydia Feinstein Social and Scientific Systems, Durham, North Carolina *Correspondence: Social & Scientific Systems, 4505 Emperor Blvd., Suite 400, Durham, North Carolina 27703 telephone: 919-287-4556; FAX: 919-941-9349; E-mail Address: [email protected] Financial interest and/or other relationship with Social & Scientific Systems. More articles by this author Julia B. Ward Social and Scientific Systems, Durham, North Carolina Financial interest and/or other relationship with Social & Scientific Systems. More articles by this author Chyng-Wen Fwu Social and Scientific Systems, Durham, North Carolina Financial interest and/or other relationship with Social & Scientific Systems. More articles by this author Ziya Kirkali National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland More articles by this author Tamara Bavendam National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland More articles by this author Brian R. Matlaga Departments of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland Financial interest and/or other relationship with Boston Scientific and Social & Scientific Systems. More articles by this author Kevin T. McVary Loyola University Medical Center, Maywood, Illinois More articles by this author Expand All The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number. The UDA (Urologic Diseases in America) project was funded by the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) through a contract to Social & Scientific Systems (HHSN276201500204U). The data reported here have been supplied in part by the USRDS (United States Renal Data System). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the United States government. No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. Editor's Note: This article is the fourth of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 212 and 213. Advertisement PDF downloadLoading ...